National projects
Range:
MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy
Ion channels are now considered unconventional, promising oncological targets, whose expression is often altered in cancer cells and which areemerging as critical players in tumorigenesis. The idea of targeting Kv1.3 ion channels directly in mitochondria, whose function critically depends onion fluxes and which are crucial for both cell survival and apoptosis, could...
Development of novel small molecule Toll-like receptors 7 and 8 modulators for cancer immunotherapy
Intracellular targets of the innate immune system that can be modulated by small molecule agents, which offer numerous advantages compared to large biopharmaceuticals, represent big opportunities in pharmacy and innovative possibility to reverse the immune tolerance in the treatment of cancer patients. One of the most important aforementioned targets are Toll-like r...
Efficacy of bacteriophages for treatment of extracellular and intracelular bacterial infections of implantants
Goal of the project is to investigate possibility of bacteriophage therapy in periprosthetic joint infections (PJI) treatment. The number of joint implants is increasing every year, as they nearly eliminate pain and contribute significantly to better mobility of the patients affected with end stage joint derangements. Along with increasing number of patients with jo...
Selective mechanical removal of bacterial biofilms by conjugated magnetic nanoparticles
Biofilms are microbial communities protected by a self-synthesized layer of extracellular polymeric substance that form on surfaces. Biofilms protect the bacteria from the host immune system and enable them to persist in adverse environmental conditions. They are an important clinical and public health problem, as up to 80% of all bacterial infections in humans ar...
01. October 2022 - 30. September 2025 | 1-09 Natural sciences and Mathematics - Pharmacy
Development of new inhibitors of bacterial topoisomerases to overcome antimicrobial resistance
In recent years, we observed an alarming increase in life-threatening infections due to resistant Gram-positive and Gram-negative pathogens and mycobacteria. Resistance has evolved to every single antibacterial drug that has been introduced to the clinic, which strongly limits our treatment options. New antibacterials specifically aimed at resistant infe...
MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance
There is an urgent need for new therapies and new antibiotics to treat deadly infections caused by so-called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species), which are often resistant to available antibiotics. Antimicrobial resistance (AMR) is becoming an ...
The kiss of death for key apoptosis players: development of BCL-2 and BAX PROTACs
The intrinsic (mitochondrial) apoptosis pathway is a physiologically dominant form of cell death and is controlled by the BCL-2 family of proteins. The members of this family have opposing effects as some of them promote and others prevent mitochondria-dependent apoptosis. The cross-talk within this family, which is governed by protein-protein interactions between p...